Poster

CIO 2023-10 Final Results of the GPX Embolic Device Multi-Center Trial for Distal Applications

Purpose: GPX is a novel aqueous-based liquid embolic agent designed for use in durable and pre-operative transcatheter embolization procedures. A prospective, multicenter first-in-human (...

Martin Krauss ;

Ryan O'Hara ;

11/01/2023

CIO 2023-7 Socioeconomic and Demographic Predictors of Transarterial Chemoembolization Outcomes for Hepatic Malignancies

Purpose: This study aimed to evaluate socioeconomic and demographic factors that predict overall survival (OS) and progression free survival (PFS) of patients undergoing transarterial che...

Xueliang Pan , PhD;

Mina S. Makary , MD;

Rohan Makhijani , BS;

Erin Niederkohr , BS;

Ian Tarnovksy , BS;

Noah Takacs , BS;

11/01/2023

CIO 2023-2 Feasibility of CT Based Tumor Dosimetry Using Multimodal Imageable Glass Eye90 Microspheres

Purpose: To demonstrate proof of concept for CT based tumor dosimetry after treatment of Hepatocellular Carcinoma (HCC) with multimodal imageable yttrium-90 (90Y) microspheres (Eye90 micr...

Amit Verma , DrPH, MPH;

David Dobrowski ;

Adam Kulp , PhD;

Eric Henry , PhD;

S. Cheenu Kappadath , PhD;

Aravind Arepally , MD;

Andrew Holden , MBChB;

11/01/2023

CIO 2023-1 Four-year Overall Survival from the HIMALAYA Study of Tremelimumab + Durvalumab in Unresectable Hepatocellular Carcinoma

Purpose: In the primary analysis (data cut-off: 27 August 2021) of the phase 3 HIMALAYA study (NCT03298451) in unresectable hepatocellular carcinoma (uHCC), STRIDE (Single Tremelimumab Re...

Yoon-Koo Kang , MD, PhD;

Charu Gupta , MSc;

Maria Reig , MD, PhD;

Peter R. Galle , MD, PhD;

Alejandra Negro , PhD;

Masatoshi Kudo , MD, PhD;

Bruno Sangro , MD, PhD;

George Tat-Ming Lau , MBBS, FRACP, MD, PhD;

Valeriy Vladimirovich Breder , MD, PhD;

Stephen Lam Chan , MD;

Robin Kate Kelley , MD;

Wattana Sukeepaisarnjaroen , MD;

Enrico De Toni , MD, PhD;

Junji Furuse , MD, PhD;

Lorenza Rimassa , MD;

Alexandra Heurgué , MD;

Vincent Tam , MD;

Tu Van Dao , MD, PhD;

Satheesh Chiradoni Thungappa , MD;

Yuriy Ostapenko , MD;

Mallory Makowsky , PharmD;

11/01/2023

Utilization of Psychiatric Pharmacogenomic Testing by Primary Care Physicians and Advanced Practice Providers: Confidence and Implementation Barriers

Routine implementation of pharmacogenomic testing for mental health and other conditions treated in primary care may require overcoming barriers such as cost to the patient and knowledge ...

Holly Johnson , PhD;

10/26/2023

Valbenazine Improves Tardive Dyskinesia With or Without Concomitant Antipsychotic Therapy: A Meta-Analysis of Three Long-Term Valbenazine Trials

Valbenazine is indicated for once-daily treatment of tardive dyskinesia (TD), a movement disorder associated with prolonged antipsychotic exposure. Data from 3 long-term studies (KINECT™-...

Bijal Sheth , PharmD;

10/26/2023

Veterans’ Intensive PCMHI Boot Camp (VIP Boot Camp)

Veterans Intensive Primary Care Mental Health Integration Bootcamp (VIP Bootcamp): An upstream solution to Mental Health(MH) access issues within the VA system

Meghan Rooney , PsyD;

10/26/2023

Viloxazine ER (Qelbree®) Administered with Psychostimulants in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: Topline Results of a Phase IV Safety Trial

Results of a phase IV, open-label safety study evaluating viloxazine ER (Qelbree®) administered with psychostimulants in pediatric (6-17 years) ADHD; morning vs. evening administration of...

Ann Childress , MD;

10/26/2023

Withdrawal Catatonia: A Rare Case of Treatment-Resistant Catatonia Secondary to Quetiapine Withdrawal

Catatonia is a psychomotor syndrome with well-defined clinical characteristics, although the neurological mechanisms involved remain unknown. In this study, we report a case of a patient ...

10/26/2023

Zuranolone Safety and Tolerability in Adults with Postpartum Depression: Analyses from SKYLARK, a 50 mg Placebo-Controlled Study

In the SKYLARK Study, zuranolone 50 mg was generally well tolerated in adults with postpartum depression; treatment-emergent adverse events (TEAEs) led to zuranolone dose reduction and di...

Judith F. Joseph , MD, MBA;

10/26/2023